Subtherapeutic oral anticoagulant therapy: Frequency and risk factors

被引:22
作者
Rombouts, Eva K. [1 ]
Rosendaal, Frits R. [1 ,2 ]
van der Meer, Felix J. M. [1 ]
机构
[1] Leiden Univ, Med Ctr, Dept Thrombosis & Haemostasis, NL-2300 RC Leiden, Netherlands
[2] Leiden Univ, Med Ctr, Dept Clin Epidemiol, NL-2300 RC Leiden, Netherlands
关键词
Oral anticoagulants; anticoagulant stability; INR; NONRHEUMATIC ATRIAL-FIBRILLATION; STROKE PREVENTION; WARFARIN; ACENOCOUMAROL; PHENPROCOUMON; QUALITY; OVERANTICOAGULATION; METAANALYSIS; MANAGEMENT; INTENSITY;
D O I
10.1160/TH08-09-0626
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Subtherapeutic anticoagulation levels increase both the risk and severity of thromboembolism. The aim of this study was to determine the cumulative incidence of subtherapeutic international normalised ratios (INRs) and to identify risk factors associated with a low INR. We performed a cohort study in 7,419 patients from a Dutch anticoagulation clinic. Patients who started a first treatment with oral anticoagulants between January 2000 and December 2005 and who were stably anticoagulated (4 consecutive INRs in the therapeutic range) were included. Within the cohort a nested case control study was performed to identify risk factors of subtherapeutic INRs and to determine how often a subtherapeutic INR is the result of medical interference in case of invasive procedures, hospital admissions, haemorrhage or overanticoagulation. In patients with a stable anti coagulation, the median time to a first low INR was 40 weeks. A subtherapeutic INR occurred twice as often in patients using acenocoumarol as in those using phenprocoumon (hazard ratio [HR] 2.1, 95% confidence interval [95%CI]:2.0 - 2.3) and was more common in patients with a high therapeutic range compared to a low therapeutic range (HR 1.8,95%CI: 1.5 - 2.2). Occurrence of a low INR also depended on indication for anticoagulant therapy, with the highest risk in patients who used anticoagulants as prophylaxis and the lowest risk in patients with mechanical heart valves. In 30% of cases the subtherapeutic INR was preceded by an event necessitating vitamin K or discontinuation of the anticoagulant drug.
引用
收藏
页码:552 / 556
页数:5
相关论文
共 25 条
[1]   Pharmacology and management of the vitamin K antagonists [J].
Ansell, Jack ;
Hirsh, Jack ;
Hylek, Elaine ;
Jacobson, Alan ;
Crowther, Mark ;
Palareti, Gualtiero .
CHEST, 2008, 133 (06) :160S-198S
[2]   Risk factors of vitamin K antagonist overcoagulation A case-control study in unselected patients referred to an emergency department [J].
Cadiou, Gwenaelle ;
Varin, Remi ;
Levesque, Herve ;
Grassi, Vanessa ;
Benichou, Jacques ;
Tiret, Isabelle ;
Dieu, Bernard ;
Lecam-Duchez, Veronique ;
Borg, Jeanne-Yvonne ;
Muller, Jean-Michel ;
Benhamou, Ygal ;
Marie, Isabelle .
THROMBOSIS AND HAEMOSTASIS, 2008, 100 (04) :685-692
[3]   OPTIMAL ORAL ANTICOAGULANT-THERAPY IN PATIENTS WITH MECHANICAL HEART-VALVES [J].
CANNEGIETER, SC ;
ROSENDAAL, FR ;
WINTZEN, AR ;
VANDERMEER, FJM ;
VANDENBROUCKE, JP ;
BRIET, E .
NEW ENGLAND JOURNAL OF MEDICINE, 1995, 333 (01) :11-17
[4]   CANADIAN ATRIAL-FIBRILLATION ANTICOAGULATION (CAFA) STUDY [J].
CONNOLLY, SJ ;
LAUPACIS, A ;
GENT, M ;
ROBERTS, RS ;
CAIRNS, JA ;
JOYNER, C .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1991, 18 (02) :349-355
[5]   WARFARIN IN THE PREVENTION OF STROKE ASSOCIATED WITH NONRHEUMATIC ATRIAL-FIBRILLATION [J].
EZEKOWITZ, MD ;
BRIDGERS, SL ;
JAMES, KE ;
CARLINER, NH ;
COLLING, CL ;
GORNICK, CC ;
KRAUSESTEINRAUF, H ;
KURTZKE, JF ;
NAZARIAN, SM ;
RADFORD, MJ ;
RICKLES, FR ;
SHABETAI, R ;
DEYKIN, D .
NEW ENGLAND JOURNAL OF MEDICINE, 1992, 327 (20) :1406-1412
[6]   Comparison of control and stability of oral anticoagulant therapy using acenocoumarol versus. phenprocoumon [J].
Fihn, SD ;
Gadisseur, AAP ;
Pasterkamp, E ;
van der Meer, FJM ;
Breukink-Engbers, WGM ;
Geven-Boere, LM ;
van Meegen, E ;
de Vries-Goldschmeding, H ;
Antheunissn-Anneveld, I ;
van't Hoff, R ;
Harderman, D ;
Smink, M ;
Rosendaal, FR .
THROMBOSIS AND HAEMOSTASIS, 2003, 90 (02) :260-266
[7]   Therapeutic quality control of oral anticoagulant therapy comparing the short-acting acenocoumarol and the long-acting phenprocoumon [J].
Gadisseur, APA ;
van der Meer, FJM ;
Adriaansen, HJ ;
Fihn, SD ;
Rosendaal, FR .
BRITISH JOURNAL OF HAEMATOLOGY, 2002, 117 (04) :940-946
[8]   Anticoagulation therapy for stroke prevention in atrial fibrillation - How well do randomized trials translate into clinical practice? [J].
Go, AS ;
Hylek, EM ;
Chang, YC ;
Phillips, KA ;
Henault, LE ;
Capra, AM ;
Jensvold, NG ;
Selby, JV ;
Singer, DE .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 290 (20) :2685-2692
[9]   Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation [J].
Hylek, EM ;
Go, AS ;
Chang, YC ;
Jensvold, NG ;
Henault, LE ;
Selby, JV ;
Singer, DE .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (11) :1019-1026
[10]   An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation [J].
Hylek, EM ;
Skates, SJ ;
Sheehan, MA ;
Singer, DE .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 335 (08) :540-546